LLY vs RTX: Which Is the Better Buy?

Side-by-side comparison of Eli Lilly and Company and RTX Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-26.
Eli Lilly and Company Β· Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction Grade B High Quality
VS
RTX Corporation Β· Industrials
$193.54
+33.0% upside to fair value
Med Conviction Grade B High Quality
QuantHub Verdict
RTX has more upside to fair value (+33.0%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric LLY RTX
Current Price $1,183.72 $193.54
Fair Value Estimate $1,208.00 $257.36
Upside to Fair Value +2.1% +33.0%
Market Cap $1,114.8B $260.9B
Forward P/E β€” β€”
EV / EBITDA 26.8x 18.1x
Price / Sales 14.0x 2.8x
Price / FCF 52.7x 21.7x
Revenue Growth YoY +47.7% +14.5%
Gross Margin 83.4% 20.3%
Operating Margin 49.7% 11.2%
Return on Equity 92.6% 11.8%
Dividend Yield 0.57% 1.46%
FCF Yield 1.9% 4.6%
Analyst Consensus Strong Buy Buy
Investment Thesis
LLY β€” Eli Lilly and Company
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
RTX β€” RTX Corporation
RTX Corporation is a $260.85 billion aerospace and defense conglomerate operating three segments β€” Collins Aerospace, Pratt & Whitney, and Raytheon β€” serving commercial aviation, military, and government customers worldwide with 180,000 employees. The business quality is high: it holds intangible-asset and switching-cost advantages rooted in long-cycle engine programs, proprietary defense electro…
Accumulation Zones
Metric LLY RTX
Zone Low $906.00 $193.02
Zone High $1,026.80 $218.76
In Buy Zone? No Yes
← LLY Research    RTX Research β†’    All Research